July 2019
Volume 60, Issue 9
Open Access
ARVO Annual Meeting Abstract  |   July 2019
Global RNA metabolic changes associated with a dominant-negative Crx mutation
Author Affiliations & Notes
  • Inez Oh
    Washington University School of Medicine, Saint Louis, Missouri, United States
  • Shiming Chen
    Washington University School of Medicine, Saint Louis, Missouri, United States
  • Footnotes
    Commercial Relationships   Inez Oh, None; Shiming Chen, None
  • Footnotes
    Support  NEI R01 EY025272 and EY012543 (to SC), T32 EY013360 and P30 EY002687 (to DOVS), CTSA grant UL1TR002345 (to WU ICTS), and unrestricted funds from Research to Prevent Blindness (to DOVS)
Investigative Ophthalmology & Visual Science July 2019, Vol.60, 1003. doi:
  • Views
  • Share
  • Tools
    • Alerts
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Inez Oh, Shiming Chen; Global RNA metabolic changes associated with a dominant-negative Crx mutation. Invest. Ophthalmol. Vis. Sci. 2019;60(9):1003.

      Download citation file:

      © ARVO (1962-2015); The Authors (2016-present)

  • Supplements

Purpose : Mutations in the cone-rod homeobox gene CRX are associated with autosomal dominant retinopathies but the underlying disease mechanisms are poorly understood. Frameshift human CRX mutations create premature stop codons, producing truncated proteins that interfere with wild-type (WT) CRX function in heterozygotes. We previously reported a mouse model of such a mutation, Crx-E168d2. The heterozygous E168d2/+ mouse shows early severe photoreceptor deficits resembling human disease, correlating with elevated ratios of mutant:WT mRNA and protein. We hypothesized that hyper-stability of E168d2 mRNA underlies the toxic accumulation of its mRNA and protein. Further, RNA-binding proteins essential for RNA stability show altered expression in diseased retinas, raising the possibility that E168d2 misregulates genes by affecting both mRNA synthesis and degradation. This study aimed to develop a high-throughput technology to measure global RNA synthesis and decay rates in normal and diseased retinas to determine if E168d2 disrupts these processes.

Methods : Thiol(SH)–linked alkylation for the metabolic sequencing of RNA (SLAMseq) was performed on retinal explants from P14 WT or E168d2/+ mice to measure RNA synthesis rates by monitoring 4-thiouridine (4sU) incorporation into newly synthesized RNA over 2 hours (h), and RNA decay rates by an 8h pulse-chase after 2h 4sU-labeling. Chemical conversion of 4sU allows detection of labeled RNA by deep-sequencing. Subsequent computational analysis profiles differences in synthesis and decay rates of individual transcripts within and between samples.

Results : SLAMseq successfully detected 4sU incorporation into newly synthesized RNA species. Among these, photoreceptor (PR)-specific transcripts (e.g. Rho, Crx, Nrl) were enriched relative to housekeeping (HK) genes (e.g. Actb, Gapdh) in WT retinas, suggesting that PR genes are more actively transcribed than HK genes. RNA decay rate shows similar differences between PR and HK genes. The fast turnover of PR-specific transcripts is consistent with the biology of metabolically active PRs. RNA synthesis and decay rates were altered for a number of genes in E168d2/+ vs. WT retinas, supporting our hypothesis that E168d2 affects both processes.

Conclusions : SLAMseq is useful for studying RNA metabolism under normal and disease conditions. Understanding the effect of altered RNA metabolism on gene misregulation could reveal gene therapy targets.

This abstract was presented at the 2019 ARVO Annual Meeting, held in Vancouver, Canada, April 28 - May 2, 2019.


This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.